Novel crystal forms, methods for their preparation and method for preparation of olanzapine
2 Assignments
0 Petitions
Accused Products
Abstract
The invention is directed to a series of novel crystalline olanzapine forms, in particular hydrated and solvated crystalline forms of olanzapine, methods of use in pharmaceutical compositions, and method of treating psychiatric disorders using the crystalline forms. One series of the crystalline forms are hydrates, i.e. water containing crystals, wherein water may be present in a ratio of about 2:1.5 to a ratio of about 1:3 olanzapine:water, while another includes solvates such as an isobutanol solvate. The olanzapine crystalline forms include Forms H, G, Y, X, K, S, Q, Z, and J.
-
Citations
68 Claims
-
1. Crystalline olanzapine isobutanol solvate.
-
2. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.7, 18.4, 19.2, 20.0, 21.1, 21.6, 22.4, 23.1, 23.6 and 24.0, ±
- 0.2 degrees two-theta.
- View Dependent Claims (3, 4, 5, 6, 66)
-
7. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 6.6, 9.0, 16.4, 17.9, 18.6, 18.8, 19.6, 22.8 and 25.2, ±
- 0.2 degrees two-theta.
- View Dependent Claims (8, 9, 10, 11)
-
12. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.4, 8.8, 9.3, 16.9, 18.4, 19.4, 20.1, 22.2, 23.1, 23.8 and 25.2, ±
- 0.2 degrees two-theta.
- View Dependent Claims (13, 14, 15, 16, 17, 67)
-
18. Crystalline olanzapine sesquihydrate.
-
19. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 9.1, 16.4, 18.5, 22.8, 23.8 and 24.3±
- 0.2 degrees two-theta.
- View Dependent Claims (20, 21, 22, 23, 24, 25, 26)
-
27. Crystalline olanzapine trihydrate.
-
28. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.8, 13.7, 16.3, 18.4, 19.6, 20.2 and 22.4±
- 0.2 degrees two-theta.
- View Dependent Claims (29, 30, 31, 32, 33, 34, 35)
-
36. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.6, 10.3, 11.4, 14.6, 19.8, 21.0, 21.5, 22.3, 23.9 and 29.7, ±
- 0.2 degrees two-theta.
- View Dependent Claims (37, 38, 39, 40, 41)
-
42. Crystalline olanzapine ¾
- hydrate.
-
43. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.7, 14.7, 17.1, 17.8, 19.9, 21.0, 21.6, 22.3, 23.9, 25.3 and 26.5±
- 0.2 degrees two-theta.
- View Dependent Claims (44, 45, 46, 47, 48, 49, 50)
-
51. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 8.8, 18.1, 18.8, 19.3, 22.9, 23.3 and 24.8±
- 0.2 degrees two-theta.
- View Dependent Claims (52, 53, 54, 55, 56, 57)
-
58. A crystalline form of olanzapine characterized by a powder X-ray diffraction pattern having peaks at about 9.0, 16.3, 18.5, 19.6, 20.0, 20.4, 22.8, 24.2, and 25.6±
- 0.2 degrees two-theta.
- View Dependent Claims (59, 60, 61, 62, 63, 64, 65)
-
68. A pharmaceutical composition comprising the forms selected from the group consisting of Forms H, G, Y, X, K, S, Q and J.
Specification